Tesamorelin Lab Monitoring: Blood Work Guide | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Tesamorelin lab monitoring

Lab guideLast updated: October 28, 2026

Which blood work to run before, during and after a tesamorelin cycle, and what the research can and can't tell you about the results. Tesamorelin is the approved drug Egrifta, for excess abdominal fat in people with HIV, and has the strongest human data of any peptide on this site: trials of more than 800 people (PMID 20554713). Its own label tells doctors to monitor IGF-1 and blood sugar, so this panel follows the label.

Read this firstThe Egrifta SV label says it is contraindicated with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), "active malignancy", known hypersensitivity, and pregnancy. It also says to "monitor patients with diabetes" at regular intervals "for potential development or worsening of retinopathy", which is an eye exam, not a blood test.

When to test

1. Baseline (before you start)

MarkerWhy test itStandard range
IGF-1
Insulin-like growth factor 1
The label says: "Monitor IGF-1 levels during EGRIFTA SV therapy." Your baseline is what every later draw is compared against.Depends on age and sex. Labcorp adult examples: ages 21-25, men 109-353 and women 101-347; ages 41-45, men 84-270 and women 74-239; ages 56-60, men 68-247 and women 60-207 ng/mL
Source: Labcorp test 010363
Fasting glucose
Fasting plasma glucose
The label says: "Evaluate glucose status prior to initiating EGRIFTA SV." Fast for at least 8 hours before the draw.Normal under 100; prediabetes 100-125; diabetes 126 or higher mg/dL
Source: American Diabetes Association
HbA1c
Hemoglobin A1c
Part of the label's glucose check. In the trials, HbA1c of 6.5% or higher by week 26 was more common on tesamorelin than placebo (5% vs 1%).Normal under 5.7%; prediabetes 5.7-6.4%; diabetes 6.5% or higher
Source: American Diabetes Association
CBC
Complete blood count
A standard safety baseline before any injectable. The label does not call for it; it gives you your own reference point if you feel unwell during the cycle.WBC 4.0-10 k/mcL; hemoglobin 13-17 g/dL men, 11.5-15.5 g/dL women; platelets 150-400 k/mcL
Source: Cleveland Clinic

2. Mid-cycle (week 4)

IGF-1 is expected to rise; the label says to monitor it

MarkerWhy test it
IGF-1
Insulin-like growth factor 1
Should be rising. In the trials, IGF-1 above the normal range showed up as early as week 13, so week 4 is an early look.
Fasting glucose
Fasting plasma glucose
The label calls for periodic glucose monitoring. Same fasting conditions as baseline.

3. Post-cycle (2-4 weeks after your last dose)

MarkerWhy test it
IGF-1
Insulin-like growth factor 1
Should be heading back toward your baseline.
Fasting glucose
Fasting plasma glucose
Confirms glucose is back where it started.
HbA1c
Hemoglobin A1c
After a 3-6 month cycle, HbA1c covers most of it. The label's diabetes signal was measured by HbA1c at 26 weeks.

Ranges differ between labs. IGF-1 ranges also depend on age, sex and the assay the lab uses, so run every IGF-1 draw at the same lab and read it against the age band printed on your own report. Glucose and HbA1c cut-offs are the American Diabetes Association's diagnostic thresholds. CBC ranges come from Cleveland Clinic.

What to expect

  • IGF-1: expected to rise (baseline to week 4, and through the cycle)

    In the 26-week trial of 412 people on 2 mg daily, IGF-1 rose 81% on tesamorelin and fell 5% on placebo (PMID 18057338). Across 806 people in the pooled trials, the mean rise was 108 ng/mL (PMID 20554713). By week 26, 47% had IGF-1 more than 2 standard deviations above normal for their age, and 36% more than 3 (Egrifta SV label).

    If it doesn't: On 2 mg daily, no IGF-1 movement at all is out of line with the trials and is consistent with an under-dose or a vial problem; check the certificate of analysis for your batch. Too high is a label issue too: it says to consider stopping with "persistent elevations of IGF-1 levels (e.g., >3 SDS)".

  • Fasting glucose and HbA1c: usually unchanged; diabetes risk is raised (baseline, week 4, post-cycle)

    The phase 3 trials found no clinically meaningful differences in glucose parameters at 26 and 52 weeks (PMID 20554713). In 53 people with type 2 diabetes, 12 weeks of tesamorelin did not change fasting glucose or HbA1c (PMID 28617838). But in the trials, HbA1c of 6.5% or higher by week 26 was more common on tesamorelin (5% vs 1%, hazard ratio 3.3), and the label says it "can result in glucose intolerance".

    If it doesn't: Fasting glucose moving into the prediabetes range (100 or higher), or HbA1c reaching 5.7% or higher, is a reason to stop and talk to a clinician.

Your labs can't check your vial

Your labs can't check your vial, though for tesamorelin IGF-1 gives a real hint: the trials set a clear expectation that it rises. No peer-reviewed study has tested grey-market tesamorelin for identity or purity, and FDA has not named it in its compounding safety review. Identity and purity get checked on the product's certificate of analysis, against the testing lab's own record.

Verify a lab certificate on ThirdPartyVerified →

What the research doesn't show

  • The trials enrolled people with HIV on antiretroviral therapy who had excess abdominal fat, mostly men (PMID 18057338). Results may not carry over to healthy adults using it for body composition.
  • The label dose is 2 mg daily. The trials did not test other doses or on-and-off cycles.
  • The label lists fluid retention (swelling, joint pain, carpal tunnel syndrome) and injection-site reactions. These are not picked up by blood tests.
  • Banned in sport: the 2026 WADA Prohibited List names tesamorelin as a GHRH analogue under S2, prohibited at all times.

Sources

  1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007. PMID 18057338
  2. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010. PMID 20554713
  3. Clemmons DR, et al. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes. PLoS One 2017. PMID 28617838
  4. FDA: EGRIFTA SV (tesamorelin for injection) prescribing information, 2019
  5. Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab 2017. PMID 29025199
  6. Labcorp test 010363: Insulin-like growth factor 1 (IGF-1), age- and sex-specific reference ranges
  7. American Diabetes Association: Diagnosis (A1C and fasting plasma glucose thresholds)
  8. Cleveland Clinic: Complete blood count (normal values for adults)
  9. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (tesamorelin not named)
  10. German Sport University Cologne (WADA-accredited lab): S2 Peptide hormones, growth factors, related substances and mimetics (2026 Prohibited List)

Educational content, not medical advice. Reference ranges differ by lab, so read your results against the range printed on your own report, and have a clinician review anything out of range.